Abstract
The potential of genomic technologies for improving the diagnosis and treatment of many human diseases will not be fully realized until several ethical, legal and social issues are addressed by effective science policy. We believe that more widespread public debate and subsequent policy action are urgently required. Here, we discuss several mechanisms by which this might occur. We propose an independent genome policy organization as an additional approach to promoting informed science policy in the age of genomics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Guttmacher, A. E. & Collins, F. S. Genomic medicine — a primer. N. Engl. J. Med. 347, 1512–1520 (2002).
Collins, F. S. & McKusick, V. A. Implications of the Human Genome Project for medical science. JAMA 285, 540–544 (2001).
Waters, M. D., Olden, K. & Tennant, R. W. Toxicogenomic approach for assessing toxicant-related disease. Mutat. Res. 544, 415–424 (2003).
Khoury, M. J., McCabe, L. L. & McCabe, E. R. Population screening in the age of genomic medicine. N. Engl. J. Med. 348, 50–58 (2003).
Olden, K., Guthrie, J. & Newton, S. A bold new direction for environmental health research. Am. J. Public Health 91, 1964–1967 (2001).
Millikan, R. The changing face of epidemiology in the genomics era. Epidemiology 13, 472–480 (2002).
Olden, K. & Wilson, S. Environmental health and genomics: visions and implications. Nature Rev. Genet. 1, 149–153 (2000).
Collins, F. S., Green, E. D., Guttmacher, A. E. & Guyer, M. S. A vision for the future of genomics research. Nature 422, 835–847 (2003).
Burke, W. Genetic testing. N. Engl. J. Med. 347, 1867–1875 (2002).
Khoury, M. J., Burke, W. & Thomson, E. J. Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease (Oxford Univ. Press, New York, 2000).
Collins, F. S. & Watson, J. D. Genetic discrimination: time to act. Science 302, 745 (2003).
Weisfeld, N. E. Mapping public policy on genetics. Gene Ther. 9, 662–666 (2002).
Peterson, A. & Bunton, R. New Genetics and the New Public Health (Routeledge, New York, 2002).
Boyle, P. J. Shaping priorities in genetic medicine. Hastings Center Report 25, S2–S8 (1995).
Fuller, B. P. et al. Privacy in genetics research. Science 285, 1359–1361 (1999).
Rothenberg, K. H. & Terry, S. F. Human genetics. Before it's too late — addressing fear of genetic information. Science 297, 196–197 (2002).
Gerard, S., Hayes, M. & Rothstein, M. A. On the edge of tomorrow: fitting genomics into public health policy. J. Law Med. Ethics 30, 173–176 (2002).
Varmus, H. E. The challenge of making laws on the shifting terrain of science. J. Law Med. Ethics 28, 46–53 (2000).
Yarborough, M. & Sharp, R. R. Restoring and preserving trust in biomedical research. Acad. Med. 77, 8–14 (2002).
Schlesinger, A. M. The Cycles of American History (Houghton Mifflin, New York, 1999).
Capron, A. M. & Shapiro, R. Remembering Asilomar? Reexamining science's ethical and social responsibility. Perspect. Biol. Med. 44, 162–169 (2001).
Berg, P. et al. Potential biohazards of recombinant DNA molecules. Science 185, 303 (1974).
Weiner, C. Drawing the line in genetic engineering. Self-regulation and public participation. Perspect. Biol. Med. 44, 208–220 (2001).
King, N. M. RAC oversight of gene transfer research: a model worth extending? J. Law Med. Ethics 30, 381–389 (2002).
Fredrickson, D. S. The first twenty-five years after Asilomar. Perspect. Biol. Med. 44, 170–182 (2001).
Berg, P. & Singer, M. The recombinant DNA controversy: twenty years later. Proc. Natl Acad. Sci. USA 92, 9011–9013 (1995).
Barinaga, M. Asilomar revisited: lessons for today? Science 287, 1584–1585 (2000).
Davatelis, G. N. The Asilomar process: is it valid? The Scientist 15, 51 (2000).
Juengst, E. T. Human genome research and the public interest: progress notes from an American science policy experiment. Am. J. Hum. Genet. 54, 121–128 (1994).
Allen, A. Policing the gene machine: can anyone control the Human Genome Project? Lingua Franca 8, 29–36 (1997).
Cook-Deegan, R. M. The Gene Wars: Science, Politics, and the Human Genome (Norton, New York, 1994).
Juengst, E. T. The Human Genome Project and bioethics. Kennedy Inst. Ethics J. 1, 71–74 (1991).
Meslin, E. M., Thomson, E. J. & Boyer, J. T. The Ethical, Legal, and Social Implications Research Program at the National Human Genome Research Institute. Kennedy Inst. Ethics J. 7, 291–298 (1997).
Marshall, E. The genome project's conscience. Science 274, 488–490 (1996).
Juengst, E. T. Self-critical federal science? The ethics experiment within the U.S. Human Genome Project. Soc. Philos. Policy 13, 63–95 (1996).
Hudson, K. L., Rothenberg, K. H., Andrews, L. B., Kahn, M. J. & Collins, F. S. Genetic discrimination and health insurance: an urgent need for reform. Science 270, 391–393 (1995).
Reilly, P. Fear of genetic discrimination drives legislative interest. Human Genome News 8, 3–4 (1997).
ELSI Research Planning and Evaluation Group. A review and analysis of the ELSI research programs at the national institutes of health and the department of energy. National Human Genome Research Institute [online], <http://www.genome.gov/10001727> (2000).
Harris Interactive. Public Awareness in the Age of Genomics [online], <http://www.harrisinteractive.com/news/allnewsbydate.asp?NewsID=317> (2001).
The Wellcome Trust. Review of the Wellcome Trust Biomedical Ethics Programme [online], <http://www.wellcome.ac.uk/en/1/pinbiorev.html> (2003).
Braun, R. People's concerns about biotechnology: some problems and some solutions. J. Biotechnol. 98, 3–8 (2002).
European Initiative for Biotechnology Education [online], <http://www.eibe.Info> (2004).
HumGen [online], <http://www.humgen.umontreal.ca/en> (2004).
Specter, M. The pharmageddon riddle. New Yorker 76, 58–71 (2000).
McHughen, A. Pandora's Picnic Basket: The Potential and Hazards of Genetically Modified Foods (Oxford Univ. Press, New York, 2000).
Gaskell, G., Bauer, M. W., Durant, J. & Allum, N. C. Worlds apart? The reception of genetically modified foods in Europe and the U.S. Science 285, 384–387 (1999).
Ferber, D. GM crops in the cross hairs. Science 286, 1662–1666 (1999).
Bosch, X. USA fights Europe's ban on genetically modified food. The Lancet 361, 1798 (2003).
Bosch, X. GM foods in new dispute. The Lancet 362, 714 (2003).
Mitchell, P. Europe angers US with strict GM labeling. Nature Biotechnol. 21, 6 (2003).
World Trade Organization. European Communities — Measures Affecting the Approval and Marketing of Biotech Products [online], http://www.wto.org/english/tratop_e/dispu_e/dispu_subjects_index_e.htm#gmos> (2003).
Kolata, G. Clone: The Road to Dolly and the Path Ahead (William Morrow and Company, New York, 1998).
Anderson, N. Human cloning success startles lawmakers. Los Angeles Times A13 (27 Nov 2001).
Isasi, R. Database of Global Policies on Human Cloning and Germ-line Engineering [online], <http://www.glphr.org/genetic/genetic.Htm> (2003).
Lenoir, N. Universal declaration on the human genome and human rights: the first legal and ethical framework at the global level. Columbia Human Rights Law Review 30, 537–561 (1999).
Carson, R. Silent Spring (Houghton Mifflin, Boston, 1962).
Whorton, J. Before Silent Spring: Pesticides and Public Health in Pre-DDT America (Princeton Univ. Press, Princeton, 1974).
Graham, F. Since Silent Spring (Houghton-Mifflin, Boston, 1970).
Ashworth, W. The Carson Factor (Hawthorn Books, New York, 1979).
Hilgartner, S. Science on Stage: Expert Advice as Public Drama (Stanford Univ. Press, Stanford, California, 2000).
Clayton, E. W. Ethical, legal, and social implications of genomic medicine. N. Engl. J. Med. 349, 562–569 (2003).
Hellman, D. What makes genetic discrimination exceptional? Am. J. Law Med. 29, 77–116 (2003).
Zitner, A. Senate blocks genetic discrimination. Los Angeles Times 16 (15 Oct 2003).
Nys, H. et al. Genetic Testing: Patient's Rights, Insurance and Employment — A Survey of Regulations in the European Union (Office for Official Publications of the European Communities, Luxemborg, 2002).
Carnegie Commission on Science, Technology and Government. Science, Technology, and Congress: Organizational and Procedural Reforms: A Report of Carnegie Commission on Science, Technology, and Government (The Commission, New York, 1994).
European Commission. Life Science and Biotechnology: A Strategic Vision [online], <http://europa.eu.int/comm/biotechnology/introduction_en.html> (2004).
Shapiro, H. T. Reflections on the interface of bioethics, public policy and science. Kennedy Inst. Ethics J. 9, 209–224 (1999).
Yudell, M. A. Accounting for the fear factor. Genome Technol. 56 (2001).
Terry, S. F. & Davidson, M. E. Empowering the public to be informed consumers of genetic technologies and services. Community Genet. 3, 148–150 (2000).
Ard, C. F. & Natowicz, M. R. A seat at the table: membership in federal advisory committees evaluating public policy in genetics. Am. J. Public Health 91, 787–790 (2001).
Caulfield, T., Gold, E. R. & Cho, M. K. Patenting human genetic material: refocusing the debate. Nature Rev. Genet. 1, 227–231 (2000).
Knoppers, B. M. Status, sale and patenting of human genetic material: an international survey. Nature Genet. 22, 23–26 (1999).
Health Effects Institute [online], <http://www.healtheffects.org> (2004).
Anderson, F. R. Science advocacy and scientific due process. Issues Sci. Technol. 16, 71–76 (2001).
Schulte, P. A. & Lomax, G. Assessment of the scientific basis for genetic testing of railroad workers with carpal tunnel syndrome. J. Occup. Environ. Med. 45, 592–600 (2003).
Weiss, R. Ignorance undercuts gene tests' potential. Washington Post A1 (2 Dec 2000).
Greely, H. T. Human genomics research. New challenges for research ethics. Perspect. Biol. Med. 44, 221–229 (2001).
Wendler, D., Prasad, K. & Wilfond, B. Does the current consent process minimize the risks of genetics research? Am. J. Med. Genet. 113, 258–262 (2002).
Rothstein, M. A. & Epps, P. G. Pharmacogenomics and the (ir)relevance of race. Pharmacogenomics J. 1, 104–108 (2001).
Weijer, C. & Miller, P. B. Protecting communities in pharmacogenetic and pharmacogenomic research. Pharmacogenomics J. 4, 9–16 (2004).
Foster, M. W., Sharp, R. R. & Mulvihill, J. J. Pharmacogenetics, race, and ethnicity: social identities and individualized medical care. Ther. Drug Monit. 23, 232–238 (2001).
Silver, L. Remaking Eden: Cloning and Beyond in a Brave New World (Avon Books, New York, 1999).
Walters, L. & Palmer, J. G. The Ethics of Human Gene Therapy (Oxford Univ. Press, New York, 1997).
Rothman, D. & Rothman, S. The Pursuit of Perfection: The Promise and Perils of Medical Enhancement (Panthoen Books, New York, 2003).
Andrews, L. B. The Clone Age: Adventures in the New World of Reproductive Technology (Henry Holt, New York, 1999).
Leary, W. E. Panel urges caution in producing gene-altered animals. New York Times A12 (21 Aug 2002).
Acknowledgements
The work reported in this publication was supported in part by the National Institute of Environmental Health Sciences and the National Human Genome Research Institute. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Environmental Health Sciences, the National Human Genome Research Institute or the National Institutes of Health. The authors wish to thank R. DeSalle and D. Rosner for their thoughtful comments on earlier versions of the paper, and M. Sander for her editorial assistance.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Sharp, R., Yudell, M. & Wilson, S. Shaping science policy in the age of genomics. Nat Rev Genet 5, 311–315 (2004). https://doi.org/10.1038/nrg1320
Issue Date:
DOI: https://doi.org/10.1038/nrg1320
This article is cited by
-
Share and share alike: deciding how to distribute the scientific and social benefits of genomic data
Nature Reviews Genetics (2007)